Schering Aktiengesellschaft

Schering Aktiengesellscaft

Roland Ekerdt

Werner Skuballa

Bernd Buchmann

Josef Heindl

Claudia Giesen

Wolfgang Frohlich

Wolfgang Fr Ohlich

Konrad Krolikiewicz

Peter Strehlke

Manfred Lehmann

Joseph Heindl

Frank Kalkbrenner

Wolfgang Fro/ Hlich

Alfred Pauls

Georg Raptis

This invention describes the use of the compounds of general formula I

Nonsteroidal anti-inflammatory agents

Leukotriene B4 derivatives, process for their production and their use

Leukotriene-B4 derivatives, process for their production and their use

The invention relates to a dermal application form of prostacyclin derivatives of Formula I ##STR1## wherein R.sub.1 means hydrogen or alkyl of 1-10 carbon atoms, A is a --CH.sub.2 --CH.sub.2 --, trans-CH.dbd.CH-- or --C.ident.C-group, W represents a hydroxymethyl group which is free or functionally modified at the hydroxy group, the OH-group being in the .alpha.- or .beta.-position, X is a CH.sub.2 -group or an oxygen atom, Z is hydrogen or a cyano group, D means a straight-chain or branched, saturated alkylene group of 1-5 carbon atoms, E is a --C.ident.C-linkage or a direct bond, R.sub.2 is a straight- or branched-chain, saturated alkyl group of 1-7 carbon atoms, R.sub.3 is a free or functionally modified hydroxy group, and, if R.sub.1 means a hydrogen atom, containing the salts thereof with physiologically compatible bases, for the treatment of ulcerations caused by arterial occlusive diseases, and other skin disorders.

Agents containing prostacyclin derivatives for topical application

Pyridine compounds which are useful as leukotriene-B.sub.4 -antagonists

Leukotriene-B.sub.4 analogs of formula I ##STR1## in which R.sup.1 means radical COOR.sup.2 with R.sup.2 meaning a hydrogen atom or a (C.sub.1 -C.sub.4)-alkyl group or R.sup.1 means radical CH.sub.2 OH,

Leukotriene-B.sub.4 antagonists, process for their production and their

New leukotriene-B4 Antagonists and their use as pharmaceutical agents

Leukotriene-B.sub.4 derivatives, process for their production and their

The present invention relates to a leukotriene-B.sub.4 analog according to formula I ##STR1## in which R.sup.1 is a COOR.sup.2 group, wherein R.sup.2 is a C.sub.2-4 -alkyl group;

Leukotriene-B.sub.4 derivatives of formula I ##STR1## are described, in which R.sup.1 means CH.sub.2 OH, CH.sub.3, CF.sub.3, COOR.sup.5, CONR.sup.6 R.sup.7, or R.sup.1 together with R.sup.2 means a carbonyl group, R.sup.4 symbolizes H, C.sub.1 -C.sub.10 alkyl optionally substituted, C.sub.3 -C.sub.10 cycloalkyl, C.sub.6 -C.sub.10 aryl radical optionally substituted, or a 5-6-membered aromatic heterocyclic ring, A symbolizes a trans, trans-CH.dbd.CH--CH.dbd.CH, a --CH.sub.2 CH.sub.2 --CH.dbd.CH-- or a tetramethylene group, B symbolizes a C.sub.1 -C.sub.10 alkylene group, which optionally can be substituted by fluorine or the group ##STR2## D can mean a direct bond, oxygen, sulfur, --C.tbd.C--, --CH.dbd.CR.sup.6 or together with B can also mean a direct bond, their salts with physiologically compatible bases and their cyclodextrin clathrates.

New leukotriene-B.sub.4 derivatives, process for their production and

1. Leukotriene-B.sub.4 antagonists of formula I ##STR1## are described, in which X is a CH.sub.2 group or an oxygen atom,

Leukotriene-B.sub.4 antagonist compounds and their use as pharmaceutical

##STR1## Compounds of formula (I) in which the residues have the following meanings: a is (II) or (III); R.sup.1 is CH.sub.2 OH, CH.sub.3, CF.sub.3, COOR.sup.5 with R.sup.5 or, A is a trans, trans--CH.dbd.CH--CH.dbd.CH--or tetramethylene group; B is an alkylene group with up to 10 C atoms; D is a direct bond, oxygen, sulphur, a --C.tbd.C--group or a --CH.dbd.CR.sup.7 --group, or (IV); B and D together are a direct bond; R.sup.2 and R.sup.3 are the same or different and denote hydrogen or an organic acid residue with 1 to 15 C atoms, R.sup.1 and R.sup.2 together are a carbonyl group; R.sup.4 is a hydrogen atom or C.sub.1-10 alkyl, and if R.sup.5 denotes a hydrogen atom, their salts with physiologically acceptable bases and their cyclodextrin clathrates.

Growing community of inventors

Berlin, Germany

Roland Ekerdt